HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

od Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Dent, Paul
izdano v Oncotarget (2017)

Correction: HDAC inhibitors enhance neratinib activity and when combined enhance the actions of an anti-PD-1 immunomodulatory antibody in vivo

od Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Dent, Paul
izdano v Oncotarget (2019)

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the BCL-2 inhibitor venetoclax to kill mammary cancer cells

od Booth, Laurence, Roberts, Jane L., Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Poklepovic, Andrew, Dent, Paul
izdano v Cancer Biol Ther (2018)

The irreversible ERBB1/2/4 inhibitor neratinib interacts with the PARP1 inhibitor niraparib to kill ovarian cancer cells

od Booth, Laurence, Roberts, Jane L., Samuel, Peter, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Poklepovic, Andrew, Dent, Paul
izdano v Cancer Biol Ther (2018)

[Neratinib + Valproate] exposure permanently reduces ERBB1 and RAS expression in 4T1 mammary tumors and enhances M1 macrophage infiltration

od Booth, Laurence, Roberts, Jane L., Rais, Rumeesa, Kirkwood, John, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Poklepovic, Andrew, Dent, Paul
izdano v Oncotarget (2017)

The levels of mutant K-RAS and mutant N-RAS are rapidly reduced in a Beclin1 / ATG5 -dependent fashion by the irreversible ERBB1/2/4 inhibitor neratinib

od Booth, Laurence, Roberts, Jane L., Poklepovic, Andrew, Kirkwood, John, Sander, Cindy, Avogadri-Connors, Francesca, Cutler Jr, Richard E., Lalani, Alshad S., Dent, Paul
izdano v Cancer Biol Ther (2017)

Induction of tumoricidal function in CD4(+) T cells is associated with concomitant memory and terminally differentiated phenotype

od Hirschhorn-Cymerman, Daniel, Budhu, Sadna, Kitano, Shigehisa, Liu, Cailian, Zhao, Feng, Zhong, Hong, Lesokhin, Alexander M., Avogadri-Connors, Francesca, Yuan, Jianda, Li, Yanyun, Houghton, Alan N., Merghoub, Taha, Wolchok, Jedd D.
Izdano 2012

Targeting tumour re-wiring by triple blockade of mTORC1, epidermal growth factor, and oestrogen receptor signalling pathways in endocrine-resistant breast cancer

od Ribas, Ricardo, Pancholi, Sunil, Rani, Aradhana, Schuster, Eugene, Guest, Stephanie K., Nikitorowicz-Buniak, Joanna, Simigdala, Nikiana, Thornhill, Allan, Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Dowsett, Mitch, Johnston, Stephen R., Martin, Lesley-Ann
izdano v Breast Cancer Res (2018)

Extended adjuvant therapy with neratinib plus fulvestrant blocks ER/HER2 crosstalk and maintains complete responses of ER+/HER2+ breast cancers: Implications to the ExteNET trial

od Sudhan, Dhivya R., Schwarz, Luis J., Guerrero-Zotano, Angel, Formisano, Luigi, Nixon, Mellissa, Croessmann, Sarah, Ericsson, Paula I. González, Sanders, Melinda E., Balko, Justin M., Avogadri-Connors, Francesca, Cutler, Richard E., Lalani, Alshad S., Bryce, Richard, Auerbach, Alan, Arteaga, Carlos L.
izdano v Clin Cancer Res (2018)

Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2)

od Cocco, Emiliano, Carmona, F. Javier, Razavi, Pedram, Won, Helen H., Cai, Yanyan, Rossi, Valentina, Chan, Carmen, Cownie, James, Soong, Joanne, Toska, Eneda, Shifman, Sophie G, Sarotto, Ivana, Savas, Peter, Wick, Michael J., Papadopoulos, Kyriakos P., Moriarty, Alyssa, Cutler, Richard E., Avogadri-Connors, Francesca, Lalani, Alshad S., Bryce, Richard P., Chandarlapaty, Sarat, Hyman, David M., Solit, David B., Boni, Valentina, Loi, Sherene, Baselga, José, Berger, Michael F., Montemurro, Filippo, Scaltriti, Maurizio
izdano v Sci Signal (2018)